Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 901–932 of 932
Lee, N. C. J., Miao, R., & Young, N. S. (2026) · Leukemia · doi:10.1038/s41375-026-02865-x
“C Median disease free survival (DFS) or 10-year DFS are plotted based on representative studies with variable endpoints of AML, myeloid neoplasia (MN), MDS/AML, and MM [1, 7, 80, 82, 113 – 115].”
Mocka, S., Ferraro, S., Trezzi, M., & Rossi, C. (2026) · ASIDE Case Reports · doi:10.71079/aside.cr.022326440
What’s New in Imaging for Multiple Myeloma
McIlroy, G., Westerland, O., & Pratt, G. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50847
Montelongo-Cepeda, J. E., Quezada-Ramírez, S. I., Alfaro, H. A. V., Fuentes-Cepeda, A. D. L., López‐García, Y. K., Colunga-Pedraza, P. R., O’Donnell, E., & Gómez‐Almaguer, D. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.006
Malik, M. A., Dalvi, A., Derkach, A., Martínez, J. A. H., Hydren, J. R., Merlo, G., Aldana, A. M., Ahlstrom, J. M., Usmani, S. Z., Chimonas, S. C., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.015
Rôle de la voie IGF-1 dans la sensibilité des plasmocytes tumoraux aux inhibiteurs du protéasome
Tagoug, I. (2010) · theses.fr (ABES) · doi:10.70675/53ca31a0z7f7fz427cz8969z2fb28a03343f
Angiogénèse et CD146 dans les gammapathies monoclonales
Cabasse, C. (2013) · theses.fr (ABES) · doi:10.70675/f5cc99e9za623z4b49z91d6z66184fe7ee3f
Ourabah, S. (2018) · theses.fr (ABES) · doi:10.70675/a0c1e5c4za32ez4d25zb6dez32fd97e19c57
Rôle du long ARN non-codant CRNDE dans le myélome multiple
David, A. (2019) · theses.fr (ABES) · doi:10.70675/0a237555z2fe4z491bz9aefz7ccb14a7bb46
Régulation épigénétique et protéique de p73 dans le Myélome Multiple
Gillardin, P. (2017) · theses.fr (ABES) · doi:10.70675/792338ecz909bz4f32zb45dz64bc1cc95f9d
Identification des marqueurs génomiques de haut risque de progression du mycosis fongoïde
Fléchon, L. (2024) · theses.fr (ABES) · doi:10.70675/4a6f0710z6ab5z4fb2z8025z49354d25f8c2
Martinez-Rivas, G. (2024) · theses.fr (ABES) · doi:10.70675/92334476z22eez4856zab28z2d443796a53d
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Nadeem, O., Aranha, M. P., Redd, R. A., Koontz, M. Z., Matous, J. V., Yee, A. J., Zonder, J. A., Kin, A. D., Magidson, S., Lightbody, E. D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71483-z
Dissecting the role of long non-coding RNA in multiple myeloma
Zocchi, S. (2024) · theses.fr (ABES) · doi:10.70675/22f35f26z6442z47d6z8cdaz153527b5df6e
Point-Counterpoint Early Intervention in Smoldering Multiple Myeloma: Pursuing Curative Strategies
Mateos, M. (2026) · The Hematologist · doi:10.1182/hem.v23.3.2026310
Li, Y., Huang, L., He, W., Wang, X., Tang, N., Zhu, D., Jia, X., & Ding, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1859289
Adrados, A., Pérez‐Fernández, J., García-Vicente, R., Garrote-de-Barros, A., Martínez‐López, J., Linares, M., & Hernández‐Sánchez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805129
Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study
Dietz, J. B., Kristjánsson, R. P., Davidsson, O. B., Rostgaard, K., Faitová, T., Rotbain, E. C., Søegaard, S. H., Thorsteinsdóttir, S., Szabo, A. G., Niemann, C. U., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-59999-2
Carlisi, M., Presti, R. L., Indelicato, S., Siragusa, S., & Caimi, G. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s599779
“10 This heterogeneity has determined the need for an accurate risk stratification, that primarily relies on tumor burden markers.”
Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies
Solia, E., Theodorakakou, F., Malandrakis, P., Ntanasis‐Stathopoulos, I., Kanellias, N., Eleutherakis‐Papaiakovou, E., Migkou, M., Spiliopoulou, V., Katsadouros, I., Giannakas, K., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70667
Sbibih, Y., Ahmidouch, K., Sebbar, E. H., & Choukri, M. A. (2026) · Next research. · doi:10.1016/j.nexres.2026.102275
Quaife, M., Jimenez‐Moreno, C., Otero, B. G., Asra, A. M., Gupta‐Werner, N., Gries, K. S., Leisten, M., Matt, K., Carson, R. L., Dennis, R. M., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2710562
“Furthermore, approximately 40% of participants were aged ≤50 years, which may not reflect the older age profile typical of real-world SMM populations [5,8], partly attributable to recruitment via social media and patient networks that inherently favor younger patients.”
InfluentialPuła, B., Ryżewska, W., Handziuk, A., Tyczyńska, A., & Kubicki, T. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2715442
“In a cohort study, Kyle et al. reported that the overall risk of progression to MM was 10% per year during the first 5 years, decreasing to 3% per year in the next 5 years, and 1% per year in the subsequent 10 years, with a cumulative probability of progression of 73% over 15 years [6].”
Tan, W., Dai, J., Kunacheewa, C., Becnel, M., Lee, H. C., Patel, K. K., Nolasco, D. B., Huang, M., Vora, A. U., Thomas, S. K., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100284
EXABS-153-MM: Should We Treat High-Risk SMM With or Without Considering Genetics?
Callander, N. S., & Gahvari, Z. J. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00305-8
Gan, G. G., Wong, L. L. L., Rahman, M. H. F. A., Boo, Y. L., Chew, L. P., Ho, K. W., Husin, A., Rajasuriar, J. S., Tan, S. M., Tan, S. K., et al. (2026) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms-03-2026-153
“Although many patients with SMM remain stable for years and do not require treatment, all have a risk of progression to MM (1, 10, 17, 19).”
Akhlaghi, T., Nemirovsky, D., Maclachlan, K. H., Firestone, R., Korde, N., Mailankody, S., Lesokhin, A. M., Hassoun, H., Patel, D., Shah, U. A., et al. (2026) · HemaSphere · doi:10.1002/hem3.70473
Smoldering and Early Disease Interception
Puertas, B., Alejo, E., & Mateos, M.-V. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000848
Carlisi, M., Presti, R. L., Mancuso, S., Giorgio, A. D., Salamone, B., Sostegno, M., Siragusa, S., & Caimi, G. (2026) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291261493017
APOBEC Status Classification Using a Curated Gene Panel in Multiple Myeloma
Vraxnos, D., Vogazianos, P., Brown, C., Lionetti, M., Entizne, J. C., Charalambous, E., Antoniades, A., & Bolli, N. (2026) · Hematological Oncology · doi:10.1002/hon.70269
Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease
Hall, J. (2014) · Repository@Hull (Worktribe) (University of Hull)
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.